Chinese biopharmaceutical company: TQB3142 clinical trial application accepted by NMPA.

China Biopharmaceutical announced on the Hong Kong Stock Exchange that the new drug clinical trial application for the innovative drug TQB3142, independently developed by the group, has been accepted by the China National Medical Products Administration, and is intended to be used for the treatment of malignant tumors.